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OBJECTIVES: To evaluate the impact of co-existing IMIDs on
health care costs in RA patients. METHODS: A retrospective
study utilizing administrative claims data from Blue Cross Blue
Shield health plans was conducted. Patients initiating anti-TNF
(inﬂiximab, etanercept, or adalimumab) therapy between January
1, 2003 and June 30, 2005, were required to have >6 months of
continuous eligibility prior to and >12 months following their
index date. Two mutually exclusive groups were developed based
on the number of IMIDs (RA, psoriatic arthritis, ankylosing
spondylitis, psoriasis, Crohn’s disease, or ulcerative colitis) diag-
noses: RA and RA plus >1 other IMID (RA + IMID). The Charl-
son-Deyo Comorbidity Index (CDCI) was used to control for
overall illness burden. IMID-attributable and all-cause health care
costs were compared between two groups. RESULTS: Of the 2409
patients, 1654 (68.7%) were diagnosed with RA and 755 (31.3%)
with RA + IMID. Over two-thirds of the patients were female
(70.5%) and the mean (SD) age was 48 + 10 years. Although the
RA group had a higher pre-period CDCI score (1.12 versus 0.71,
p < 0.0001), during the 12-month post period, it had lower IMID-
attributable costs ($15,146.83 versus $16,162.44; p = 0.5567),
and all-cause health care costs ($21,412.68 versus $22,419.36; p
= 0.2769) compared to the RA + IMID group. After adjusting for
confounding variables (age, gender, and CDCI score) via multi-
variate analysis, there were signiﬁcant differences (p < 0.05)
between the IMID-attributable and all-cause costs of the groups.
Also, compared to the RA + IMID group, the RA group had lower
costs in each health service category: inpatient admissions, out-
patient services, physician visits, emergency room visits, and phar-
macy costs. CONCLUSION: This study indicates that co-existing
IMIDs increase health care costs in patients with RA. Anti-TNF
therapy may be more cost-effective in the treatment of patients
with more than one IMID. Additional analyses are needed to
examine the effectiveness of anti-TNF therapies in patients with
more than one IMID.
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OBJECTIVES: The purpose of this study is to quantify the 
correlates and consequences of scenario rejection in a study of
stated preferences for rheumatoid arthritis (RA) treatments.
METHODS: An on-line panel of RA patients completed a stated-
choice survey. that required respondents to choose among ten
pairs of treatment alternatives with different treatment features
and a current-treatment alternative. Subjects who refuse to cor-
rectly complete the tradeoff tasks in a stated-preference survey
may reject the hypothetical-treatment scenarios in 3 ways: refuse
to answer any of the trade-off questions, answer all the ques-
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OBJECTIVES: Anti-TNF-α drugs (Biologics) have become a cor-
nerstone in the treatment of Rheumatoid Arthritis (RA). Since
initial choice of agents is sometimes driven by expected treatment
costs and related cost-effectiveness, we assessed the cost-
effectiveness of Etanercept (ETA) and Inﬂiximab (INF) based on
published real-world data from the German Biologics Registry.
METHODS: We designed an excel-based cost-effectiveness model
and calculated the costs per LUNDEX responder month. The
LUNDEX score developed by Kristensen et al. (2006) is com-
bining the proportion of patients fulﬁlling a selected response cri-
terion (e.g. ACR 20) with the proportion of patients adhering to
a therapy. Our model compares the costs per LUNDEX-response
over six months for the treatment with ETA and INF from a payer-
perspective and calculates the cost per LUNDEX responder
month. ACR 20 response rates (INF = 46%; ETA = 58%), adher-
ence to therapy (INF = 77%, ETA = 82%) and real-world dosing
data (INF = 4 mg/kg body weight, ETA = 47.5 mg/week) were
derived from published registry data. Drug costs were calculated
based on list prices. Administration and lab costs were derived
from ofﬁcial databases. RESULTS: During the ﬁrst six months,
treatment with INF or ETA causes costs of EUR 10.873 € and
EUR 9.683 €, respectively. The LUNDEX index at six months is
0.357 for INF and 0.477 for ETA. Accordingly, the costs per
LUNDEX response are 30.277 € for INF and 20.167 € for ETA.
The average cost per LUNDEX-responder month in Germany is
€5.033 for INF and € 3.362 for ETA during the ﬁrst six months
of treatment. CONCLUSION: ETA is more cost-effective than
INF in a real-world setting in Germany. Our cost-effectiveness
analysis supports decision making based on a combined measure
of response and therapy adherence. Long-term data on both
response and adherence are needed to further assess real-world
cost-effectiveness of Biologics.
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